The present invention provides among other things a composition of a polymeric reagent and an antioxidant, such as butylated hydroxyl toluene.

The present invention provides among other things a composition of a polymeric reagent and an antioxidant, such as butylated hydroxyl toluene.

Without limitation, some embodiments comprise a method of treatment for promoting recovery of peripheral neuropathy in a subject, including administering to a subject in need of such treatment a therapeutically effective amount of a composition comprised of thymosin beta 4, amino acid sequences LKKTET or LKKTNT, and/or any conservative variants thereof, or an agent that stimulates production of any of those materials, or a conservative variant thereof.

The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

The present invention relates to compositions of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof.

The present invention provides peptides comprising a sequence of X-.sub.6X-.sub.5X-.sub.4X-.sub.3X-.sub.2X-.sub.1X.sub.1PX.sub.3X.sub.4PX.sub.6X.sub.7P-GX.sub.10X.sub.11AX.sub.13X.sub.14X.sub.15X.sub.16LX.sub.18X.sub.19X.sub.20X.sub.21X.sub.22X.sub.23LX.sub.25X.sub.26YLX.sub.29X.sub.30X.sub.31X.sub.32 wherein the amino acids X.sub.-6, X.sub.-5, X.sub.-4X.sub.-3, X.sub.-2, X.sub.-1, X.sub.1, X.sub.3, X.sub.4, X.sub.6, X.sub.7, X.sub.10, X.sub.11, X.sub.13, X.sub.14, X.sub.15, X.sub.16, X.sub.18, X.sub.19, X.sub.20, X.sub.21, X.sub.22, X.sub.25, X.sub.26, X.sub.29, X.sub.30, X.sub.31, and X.sub.32 are as defined herein. The present invention further provides pharmaceutical compositions comprising the peptides and methods of using the peptides. Also provided are methods of screening a library of peptide dimers using a peptide dimer display technology.

The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.

The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.

The present invention relates to the field of biopharmaceuticals, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a GIP receptor binding polypeptide or an analogue thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in marked reduction in side effects.

The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorders.